Revolution Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Revolution Medicines, Inc. (RVMD) announced that their CEO will deliver a corporate presentation at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024, to discuss the development of targeted therapies for RAS-addicted cancers.

REDWOOD CITY, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will deliver a corporate presentation as part of the 42^nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 11:15 a.m. PT.

To access the live webcast of the presentation, please visit the “Events & Presentations” page of Revolution Medicines’ website at https://ir.revmed.com/events-and-presentations. Additionally, a replay of the webcast will be available on the “Events & Presentations” page of the Revolution Medicines website for at least 14 days following the conference.

About Revolution Medicines, Inc.
Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS companion inhibitors for use in combination treatment strategies. The company’s RAS(ON) inhibitors RMC-6236, a RAS(ON) multi-selective inhibitor, RMC-6291, a RAS(ON) G12C-selective inhibitor, and RMC-9805, a RAS(ON) G12D multi-selective inhibitor, are currently in clinical development. Additional RAS(ON) mutant-selective inhibitors in the company’s development pipeline include RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839 (G13C).

FAQ

What is the date of the 42nd Annual J.P. Morgan Healthcare Conference presentation by Revolution Medicines, Inc. (RVMD)?

The presentation is scheduled for Tuesday, January 9, 2024.

What type of therapies is Revolution Medicines, Inc. (RVMD) developing?

Revolution Medicines, Inc. is developing targeted therapies for RAS-addicted cancers.

Who will deliver the corporate presentation at the conference for Revolution Medicines, Inc. (RVMD)?

Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will deliver the presentation.

Where can I access the live webcast of the presentation by Revolution Medicines, Inc. (RVMD)?

The live webcast will be available on the “Events & Presentations” page of Revolution Medicines’ website at https://ir.revmed.com/events-and-presentations.

How long will the replay of the webcast be available for the presentation by Revolution Medicines, Inc. (RVMD)?

The replay of the webcast will be available for at least 14 days following the conference on the “Events & Presentations” page of the Revolution Medicines website.